Hepatocellular Carcinoma Clinical Trial
Official title:
Adjuvant α-Interferon Treatment After Resection of Hepatocellular Carcinoma in HCV-Related Cirrhosis: a Randomized Trial on Prevention of Cancer Recurrence
We conducted a randomized controlled trial of adjuvant interferon (IFN) therapy in patients with hepatitis-C virus (HCV)-related cirrhosis who underwent curative resection of hepatocellular carcinoma (HCC) to investigate whether IFN could reduce or delay the incidence of recurrent tumor (secondary/tertiary prevention of HCC). Patients were randomly assigned to treatment with IFN (3MU thrice/wk /48 weeks) vs. no treatment after curative resection of HCC(control group)
Background
Primary liver cancer (hepatocellular carcinoma, HCC) remains a major cancer-related cause of
death with an estimated incidence of 1 million cases per year worldwide and particular
endemic distribution related to chronic hepatitis carriers. Post-necrotic cirrhosis due to
chronic infection by HBV and HCV is the leading background for HCC development with a yearly
rate of 3% and a 5-year probability of survival of 20%.
Liver surgery, resection or transplantation, appears the only chance of curative treatment
of the tumor, but feasibility is still ranging from 15 to 30% in Western countries at time
of diagnosis. Several alternative treatments are available but their potential curative
effects are lacking, due to the absence of controlled trials.
Liver resection is claimed to be feasible in order 15-30% of patients with HCC with
mortality reported in major centers extremely low (5%). Technical and biological devices
developed in the setting of OLT can now support the limited reserve of cirrhotic livers
after resection.
Regulated segmentectomy is advisable with removal of the whole portal territory belonging to
the tumor. Single nodule tumors (< 5 cm) and compensated cirrhosis (Child class A) are
accepted as the best candidates for liver resection that now can be performed with minimal
blood loss, and minimal ischemia damage. Intraoperative ultra sound examination is now
routinely used as the golden standard for staging and detection of previously undiscovered
neoplastic nodules. Hepatic decompensation with ascites development, cholestasis and
variceal bleeding within three months from surgery are the main negative prognostic factors
for patient survival. Five years survival exceed 50% but tumor recurrences due to cirrhosis
persistence could exceed 30% after three years of follow-up. Several attempts to reduce
recurrence through antiangiogenetic and antiproliferative agents have been proposed.
In the present project a prospective randomized trial of Interferon (as antiproliferative
drug) versus control in anti-HCV positive patients will investigate in homogeneous
categories of resected tumor possible variation in the natural history and namely a
reduction of recurrence rate after curative resection.
Purpose and Study Design
The trial was intentionally designed in 1997 as an unresticted collection of patients with
histologically proved HCC and a HCV-related cirrhosis selected for surgical resection of the
tumor in 4 experienced surgical Liver Units in Italy. Eligible patients were stratified on
the basis of concomitant anti-core antibodies against HBV (anti-HBc) into two populations:
“pure HCV” (HCV-RNA:positive, anti-HBc:negative) and “mixed HCV+HBV” (HCV-RNA:positive,
anti-HBc:positive). Within each strata patients were then randomized in a 1:1 ratio to
treatment with α-interferon (IFN) vs. no treatment (control). No restriction criteria were
applied to tumor stage, as far as the resection of HCC was judged as potentially curative at
pre-operative staging, intra-operative ultrasound and post-operative pathology (clearance of
surgical margins).
The study was originally designed for lymphoblastoid α-interferon; then soon after trial
approval by the NCI-Milan Scientific and Ethic Committee (#98-016) the protocol was amended
for allowing also the use of recombinant α-2a (Roferon-A, Hoffmann-La Roche, Nutley NJ) or α
-2b interferon (Intron-A, Schering-Plough, Kenilworth, NJ). The latter was eventually the
preferred form. Patients allocated to treatment received IFN 3 MU/thrice weekly for 48 weeks
starting within 6 weeks from the operation. The severity of adverse events during treatment
were monitored and rated. Therapy was discontinued in case of life-threatening adverse event
or in case of HCC recurrence during treatment. For severe events other than anemia the IFN
dose was reduced by 50%; full dose could be resumed after the event was resolved or
discontinued if the effect persisted. The percentage of the total predicted dose of IFN
actually assumed by each patients was recorded. Patients assuming at least 80% of the total
dose of IFN and treated for at least 80% of the expected duration of therapy were a priori
defined as adherent to therapy.
Recurrences were a priori defined as “early” or “late” whether or not they occurred within 2
years from the surgical removal of the HCC. In fact early recurrence were related to
intra-hepatic metastases of the primary tumor possibly missed at the time of therapy, while
late recurrence might be due to new cancer foci related to the persistence of HCV-related
carcinogenetic factors.
Primary endpoint of this randomized clinical trial (RCT) was recurrence-free survival (RFS)
while the secondary endpoint were disease-specific survival (DSS) and overall survival (OS).
Further secondary endpoints were the assessment of IFN tolerability in post-surgical
patients and the observation of prognostic factors related to early or late recurrence.
Adherent patients were considered for a subgroup analysis focused on patients who
effectively received the treatment designed to prevent HCC recurrence.
Enrolment for the trial started on June 1998. By December 2002 the predicted sample size of
150 randomized patients was completed (“pure HCV”: 80 and “mixed HCV+HBV”: 70). The baseline
clinical, laboratory and tumor characteristics of the two arms and viral strata were
comparable. After 45 months of median follow-up the three- and five- years survival rates
were 69% and 52.4% respectively for the control group and 77.3% and 63.6% respectively for
the IFN group (P= 0.471) . At the univariate analysis tumor multiplicity (>1 nodule) and
vascular invasion were significantly related to recurrence. After adjustment of the relative
weight of prognostic factors in a series of Cox models and cumulative incidence curves
calculated on pattern of recurrence, a benefit of IFN was observed on late recurrence
occurring in the pure-HCV patients adherent to treatment (hazard rate: 0.3; 95% Confidence
interval:0.09-0.9, P=0.04).
In conclusion, although adjuvant IFN failed to show a generalized effect on prevention of
HCC recurrence after curative resection, it effectively reduced late recurrence due to new
tumor foci in pure-HCV patient adherent to therapy (i.e.: receiving at least 80% of IFN dose
for at least 80% of time).
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04209491 -
Interest of the Intervention of a Nurse Coordinator in Complex Care Pathway
|
||
Completed |
NCT03963206 -
Cabozantinib toLERANCE Study in HepatoCellular Carcinoma (CLERANCE)
|
Phase 4 | |
Completed |
NCT03268499 -
TACE Emulsion Versus Suspension
|
Phase 2 | |
Recruiting |
NCT05263830 -
Glypican-3 as a Prognostic Factor in Patients With Hepatocellular Carcinoma Treated by Immunotherapy
|
||
Recruiting |
NCT05044676 -
Immune Cells as a New Biomarker of Response in Patients Treated by Immunotherapy for Advanced Hepatocellular Carcinoma
|
||
Recruiting |
NCT05095519 -
Hepatocellular Carcinoma Imaging Using PSMA PET/CT
|
Phase 2 | |
Recruiting |
NCT05497531 -
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
|
N/A | |
Completed |
NCT05068193 -
A Clinical Trial to Compare the Pharmacokinetics and Bioequivalence of "BR2008" With "BR2008-1" in Healthy Volunteers
|
Phase 1 | |
Active, not recruiting |
NCT03781934 -
A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations
|
Phase 1/Phase 2 | |
Terminated |
NCT03655613 -
APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04242199 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT04401800 -
Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma
|
Phase 2 | |
Withdrawn |
NCT05418387 -
A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona
|
N/A | |
Active, not recruiting |
NCT04039607 -
A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
|
Phase 3 | |
Terminated |
NCT03970616 -
A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT04118114 -
Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT06239155 -
A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03642561 -
Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE
|
Phase 2/Phase 3 | |
Completed |
NCT03222076 -
Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer
|
Phase 2 |